<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="129329">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01766076</url>
  </required_header>
  <id_info>
    <org_study_id>HS1258</org_study_id>
    <nct_id>NCT01766076</nct_id>
  </id_info>
  <brief_title>Atorvastatin for HAART Suboptimal Responders</brief_title>
  <official_title>Use of Atorvastatin as Adjuvant Therapy Among Suboptimal Responders to Antiretroviral Therapy in an African Cohort of HAART-treated Adults: A Randomised Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Makerere University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Makerere University</source>
  <oversight_info>
    <authority>Uganda: National Council for Science and Technology</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      We hypothesise that atorvastatin changes immune activation among HAART-treated adults with
      suboptimal CD4 recovery by 25%
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators have previously shown that up to 40% of HAART-treated adults have
      suboptimal CD4 recovery despite viral suppression. The investigators have also shown that
      immune activation and exhaustion are significantly higher among patients that do not exhibit
      satisfactory rise in CD4 counts despite viral suppression (suboptimal responders); when
      compared with their counterparts with viral suppression and satifactory CD4 count recovery
      (optimal responders). Given that atorvastatin changes immune activation in this pilot study,
      then larger studies can be done to understand its effect on CD4 count increase among
      suboptimal responders.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">February 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Caregiver, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change of immune activation levels by 25% after 12 weeks of atorvastatin 80mg daily</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Immune activation levels will be measured before and after administration of the intervention drug (atorvastatin, Lipitor®) and will be compared among patients that take drug and placebo.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Acquired Immune Deficiency Syndrome Virus</condition>
  <arm_group>
    <arm_group_label>atorvastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention is be atorvastatin  (40mg) 2 tablets daily (as adjuvant to HAART) for 12 weeks.
PBMC will be collected for immune activation assays using flowcytometry</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intervention for the placebo comparator arm is Placebo 2 tablets daily for 12 weeks PBMC will be collected for immune activation assays using flowcytometry</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>'atorvastatin, Lipitor®'</intervention_name>
    <description>PBMC collected for immune activation assays using flowcytometry</description>
    <arm_group_label>atorvastatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>PBMC collected for immune activation assays using flowcytometry</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  HIV-infected adults on antiretroviral therapy for at least 6 years with sustained
             viral suppression (viral load&lt;400 copies)

          -  CD4 increase below 300 cells (difference between current and baseline CD4 count).

        Exclusion Criteria:

          -  History of an opportunistic infection within the previous six months

          -  Pregnancy

          -  History of myositis

          -  History of ingestion of lipid-lowering agents at the baseline visit

          -  Use of therapeutic agents known to have substantial drug-drug interactions with
             statins Individuals on PI-containing HAART
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Damalie Nakanjako, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Makerere University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Damalie Nakanjako, MD, PhD</last_name>
    <phone>+256772411273</phone>
    <email>drdamalie@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Isaac Ssinabulya, MD</last_name>
    <email>ssinabulya@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Infectious Diseases Institute</name>
      <address>
        <city>Kampala</city>
        <state>East Africa</state>
        <country>Uganda</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Uganda</country>
  </location_countries>
  <reference>
    <citation>Ganesan A, Crum-Cianflone N, Higgins J, Qin J, Rehm C, Metcalf J, Brandt C, Vita J, Decker CF, Sklar P, Bavaro M, Tasker S, Follmann D, Maldarelli F. High dose atorvastatin decreases cellular markers of immune activation without affecting HIV-1 RNA levels: results of a double-blind randomized placebo controlled clinical trial. J Infect Dis. 2011 Mar 15;203(6):756-64. doi: 10.1093/infdis/jiq115. Epub 2011 Feb 15.</citation>
    <PMID>21325137</PMID>
  </reference>
  <reference>
    <citation>Nakanjako D, Ssewanyana I, Mayanja-Kizza H, Kiragga A, Colebunders R, Manabe YC, Nabatanzi R, Kamya MR, Cao H. High T-cell immune activation and immune exhaustion among individuals with suboptimal CD4 recovery after 4 years of antiretroviral therapy in an African cohort. BMC Infect Dis. 2011 Feb 8;11:43. doi: 10.1186/1471-2334-11-43.</citation>
    <PMID>21299909</PMID>
  </reference>
  <verification_date>January 2013</verification_date>
  <lastchanged_date>January 9, 2013</lastchanged_date>
  <firstreceived_date>December 10, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Makerere University</investigator_affiliation>
    <investigator_full_name>Faculty of Medicine</investigator_full_name>
    <investigator_title>Lecturer</investigator_title>
  </responsible_party>
  <keyword>immune activation</keyword>
  <keyword>antiretroviral therapy</keyword>
  <keyword>atorvastatin</keyword>
  <keyword>immune exhaustion</keyword>
  <keyword>adults</keyword>
  <keyword>Africa</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Atorvastatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
